Navigation Links
Zosano Pharma, Inc. Appoints Nandan Oza as Chief Operations Officer

FREMONT, Calif., May 14, 2013 /PRNewswire/ -- Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, announced today a key addition to its executive team with the appointment of Nandan Oza as the company's Chief Operations Officer. In this position, Mr. Oza will guide the company's efforts in manufacturing, quality and engineering – vital activities to enable the company to accelerate the development of its innovative multi-product portfolio.

"I am pleased to welcome Nandan as our COO," said Vikram Lamba, Chief Executive Officer, Zosano Pharma. "His operational and manufacturing experience and expertise – as well as his leadership experience – will be critical in preparing Zosano for our next stage of commercial-scale manufacturing as we drive our clinical programs towards the marketplace."

Prior to joining Zosano Pharma, Mr. Oza served as Vice President, Chemistry, Manufacturing and Controls at Talon Therapeutics. He previously held the position of Vice President, Manufacturing and Supply Chain Operations at Jazz Pharmaceuticals and at Connetics Corporation (now a part of GSK). Mr. Oza also held positions of increasing responsibility at ALZA Pharmaceuticals (now part of Johnson and Johnson) in Product Development, Quality and Technical and Manufacturing Operations, progressing to his role as Executive Director, Bay Area Operations. Mr. Oza earned a Bachelor's degree (with honors) in Mechanical Engineering from the University of Houston, pursued graduate studies in Engineering from the University of California, Davis and earned an MBA from National University, San Diego, CA.

"This is an exciting time to join the Zosano Pharma team," said Mr. Oza. "The company is well positioned to move forward in commercial scale manufacturing with its ZP Patch Technology and advancing development-stage product pipeline."

About Zosano Pharma
Zosano Pharma, Inc. is a private biopharmaceutical company and a pioneer in the field of drug delivery systems. Zosano is developing products using ZP Patch Technology, a novel transdermal delivery technology based on microprojections that provide rapid and efficient systemic delivery in a convenient, needle–free, and pain–free system. Zosano is a fully integrated development company with a recently launched cGMP manufacturing capability. The company is developing products with significant commercial potential both independently and in collaboration with strategic partners. Learn more at

SOURCE Zosano Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Zosano Pharma, Inc. Expands Board of Directors with Addition of Kleanthis G. Xanthopoulos, Ph.D.
2. Zosano Pharma, Inc. Announces Key Strategic Hire
3. DFH Pharma, USA Partners with Hetero Group, INDIA to Develop 2nd Generation HIV Maturation Inhibitor Drugs
4. Morning Research on Sequenom, Peregrine Pharma, Onyx Pharma, and Inovio Pharma
5. Todays Research on PDL BioPharma, Dendreon, Medivation, ACADIA Pharma, and Cell Therapeutics
6. Robbins Arroyo LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Hemispherx Biopharma, Inc.
7. InnoPharma, Inc., Announces U.S. FDA Approval of Acetylcysteine Solution, USP, 20% for Inhalation or Oral Administration
8. Galena Biopharma, Inc. Investor Presentation Now Available for On-demand Viewing at
9. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
10. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
11. Optimer Pharmaceuticals Appoints Eric Sirota as Chief Operating Officer
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda SyMRI ... (MR-bilder) för patienter med multipel skleros ... forskningsavtal med SyntheticMR AB för att kunna ... på sjukhuset. Med SyMRI kan man generera ...
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new ... Italian therapeutic drug monitoring market, including emerging tests, ...
(Date:11/25/2015)... 25, 2015  Amgen (NASDAQ: AMGN ) today ... with the United States (U.S.) ... biosimilar candidate to Humira ® (adalimumab). Amgen believes ... to the FDA and represents Amgen,s first BLA submission ... Harper , M.D., executive vice president of Research and ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Medical Solutions, ... again for its stellar workplace culture with the company’s Cincinnati office being named ... Solutions’ Cincinnati office was named a finalist in Cincinnati Business Courier’s 13th annual ...
(Date:11/25/2015)... ... , ... Ministers, senior government and UN agencies, representatives from ... Excellence, and public R&D institutions, civil societies and other partners gathered today at ... Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. The three- day meeting ...
(Date:11/25/2015)... Los Angeles, CA (PRWEB) , ... November 25, 2015 , ... ... advanced da Vinci surgical robot is being more and more widely heralded as a ... robotic assisted da Vinci method has over traditional laparoscopic surgery is that it can ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, officials of ... Narconon network, announced the release of a new cutting edge recovery program that has ... been working with drug- and alcohol-addicted individuals with the purpose to free addicts from ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 23rd 2015 Cozy ... personal heating products business. Cozy Products explains what this means for business moving ... well with the Cozy Products business model: to sell personal heaters that reduce energy ...
Breaking Medicine News(10 mins):